Navigation Links
Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
Date:2/25/2010

BUFFALO, N.Y., Feb. 25 /PRNewswire/ -- Kinex Pharmaceuticals has appointed Rudolf Kwan, MD, as Chief Medical Officer.  

Dr. Kwan has had a successful career in the pharmaceutical industry and brings to Kinex over twenty years of experience in clinical operations.  Most recently he served dual roles at Schering Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS.

In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific.  

As Vice President of Global Clinical Development, CNS, Dr. Kwan was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration.  He also designed and executed multiple phase 2 development programs.

Earlier at Schering Plough, Dr. Kwan held various clinical operation positions with increasing responsibility.  He held similar positions at Chiron Corporation and at Smith Kline Beecham.

Dr. Kwan obtained an MD degree in Hong Kong and did subsequent training in England.  He has served as Chair of the Data Monitoring and Safety Board for the National Institute on Deafness and other Communication Disorders for trials on Celecoxib as an adjunct to surgery for Recurrent Respiratory Papillomatosis. Currently, he is a member and Chair, of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse (NIDA) of the National Institute of Health.  He is also a member of several advisory panels and grant review panels for NIDA.

"Kinex Pharmaceuticals is extremely pleased to announce that Dr. Rudolf Kwan is joining us as Chief Medical Officer.  He brings with him a distinguished career of achievements in clinical operations in the pharmaceutical industry," said Dr. Allen Barnett, CEO of Kinex.  

At Kinex Pharmaceuticals, Dr. Kwan will be responsible for the design and execution of the Company's clinical development programs.  In 2010, Kinex will be launching several Phase 2 studies in oncology for KX2-391 as well as a Phase 1 trial in brain cancer for KX2-361.  "Dr. Kwan's appointment comes at a critical point in our Company's development as we transition from a drug discovery company to a development company with multiple compounds in clinical development," said Dr. Barnett.

About Kinex Pharmaceuticals

Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company's platform technologies, Mimetica™ and Opal™, provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.

KX2-391 is currently being studied in a Phase 2 clinical trial in prostate cancer patients; additional Phase 2 oncology studies will commence later in 2010. KX2-361 is being developed for brain cancer; an IND is expected during the 4th quarter of 2010. In addition, Kinex is developing several other new product candidates that inhibit key immuno-inflammatory pathways.

For more information, visit www.kinexpharma.com.

SOURCE Kinex Pharmaceuticals

Back to top

RELATED LINKS
http://www.kinexpharma.com

'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009
3. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
4. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
5. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
6. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Innovative University of Cincinnati Program Trains Next Generation of Pharmaceutical Professionals
9. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
10. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
11. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... IRVINE, Calif. , May 25, 2016 /PRNewswire/ ... of testing for their new reference materials that ... workflows from sample collection to analyses. The rapid ... the demand for researchers to have standard methods ... data being generated. Biases inherently exist at every ...
(Date:5/25/2016)... Florida , May 25, 2016 ... Conference & Expo earlier this month, the numbers and ... revenues continue to climb into the billions, more research ... newly released 4th Edition State of Legal Marijuana Markets ... a cannabis-focused data-analysis firm, much of the increase in ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially launch our ... day issues, struggles and obstacles veterans’ need to overcome in order to face their ... or retired military veteran(s) with a donated SuperCloset product based on the needs and ...
(Date:5/27/2016)... Angeles, CA (PRWEB) , ... May 27, 2016 , ... ... of Health, so it is not surprising that bariatric surgery has received increased attention ... Business Journal explains. Of course, when it comes to weight loss, most people are ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, courtesy of leaders in the nursing and ... within the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , ...
Breaking Medicine News(10 mins):